Tociliuzumab vs placebo or usual care
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.9 [0.72, 1.12]13 studies · 2117 participantsLow